CTS™ AIM V™ SFM

Citations & References (31)

Gibco™

CTS™ AIM V™ SFM

Name: CTS™ AIM V™ SFM
SKU: 0870112DK
Price: 309.00 EUR

CTS AIM V SFM is a defined, serum-free medium (SFM) for the proliferation and/or manipulation of T cells, dendritic cells, and other immune cells manufactured in compliance with cGMP.

Change view

Catalog Number	Quantity
0870112DK	1 L
0870112BK	10 L

2 Options

Catalog number 0870112DK

Price (EUR)

309,00

Each

Add to cart

Quantity:

1 L

Price (EUR)

309,00

Each

Add to cart

Gibco Cell Therapy Systems (CTS) AIM-V SFM is a defined, serum-free medium specifically designed for the proliferation and/or manipulation of T cells, dendritic cells, and other immune cells that is manufactured in compliance with current Good Manufacturing Practice (cGMP) standards.

CTS AIM V SFM contains L-glutamine, 50 μg/mL streptomycin sulfate, and 10 μg/mL gentamicin sulfate.

CTS quality

Gibco CTS products are manufactured at a site that uses methods and controls that conform to cGMP for medical devices, 21 CFR Part 820. Our FDA-registered manufacturing sites are ISO 13485-certified. Gibco CTS products follow USP 'ancillary materials for cell, gene, and tissue-engineered products' within the responsibilities applicable to a supplier.*

Accompanied by documentation to support your regulatory filing

Specific intended-use statements, full documentation traceability, and convenient access to our Drug Master File (DMF) are available.

*Other aspects of USP will be the responsibility of the end-user to assess. Thermo Fisher Scientific cannot fulfill USP in regards to application and therapy-specific aspects (e.g., residual assessment and removal of the Ancillary Material).

For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals.

Specifications

Cell TypeMonocytes, Dendritic Cells, T Cells, Hybridomas, PBMCs, Fibroblasts, Macrophages, Myeloma Cells, Lymphocytes

For Use With (Application)Cell and Gene Therapy Research, Development, and Manufacturing

FormatBottle

Manufacturing QualityISO 13485, MDSAP, FDA-registered, 21 CFR 820

Product TypeCell Culture Medium

Quantity1 L

Shelf Life14 months from date of manufacture

Shipping ConditionAmbient

ClassificationAnimal Origin

FormLiquid

Serum LevelSerum-free

SterilitySterile-filtered

Unit SizeEach

Contents & Storage

Store at 2–8°C and protect from light.

Frequently asked questions (FAQs)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between AIM V Medium (Cat. Nos. 12055083, 12055091) and CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK)?

The difference is in the intended usage of the two media. AIM V Medium (Cat. Nos. 12055083, 12055091) is for research use only whereas CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK) is for research use or manufacturing of cell, gene, or tissue-based products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between CTS AIM-V Medium and CTS AIM V SFM?

These two media have comparable performance and same cGMP quality. The main difference is that CTS AIM-V Medium (Cat. Nos. A3830801, A3830802, A4672701) does not contain phenol red and antibiotics. This medium formulation has been used as an ancillary reagent in a therapeutic cancer vaccine approved by FDA.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (31)

Citations & References

Abstract

Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.

Authors:Genescà M, Rourke T, Li J, Bost K, Chohan B, McChesney MB, Miller CJ,

Journal:J Immunol

PubMed ID:17878372

'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific ... More

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,

Journal:Cancer Immunol Immunother

PubMed ID:19894047

'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More

[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]

Authors:Nomura K, Fujioka T,

Journal:Nippon Hinyokika Gakkai Zasshi

PubMed ID:8320888

'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily ... More

Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.

Authors:Martinuzzi E, Scotto M, Enée E, Brezar V, Ribeil JA, van Endert P, Mallone R

Journal:J Immunol Methods

PubMed ID:18242633

'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the ... More

CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells.

Authors:Johansen P, Stamou P, Tascon RE, Lowrie DB, Stockinger B,

Journal:Eur J Immunol

PubMed ID:14971034

We studied the contribution of CD4 T cell help to survival and competitive fitness of CD8 memory T cells specific for influenza virus nucleoprotein. In agreement with recent studies, the optimal generation of functional memory CD8 T cells required CD4 help, although long-term maintenance of resting CD8 memory T cells ... More

View all CTS™ AIM V™ SFM citations